Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Other Non-Current Liabilities data on file, last reported at $278000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 14.4% year-over-year to $278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278000.0 (up 14.4% YoY) and the FY2025 annual result came in at $260000.0, up 12.55% from the prior year.
• Other Non-Current Liabilities fell to $278000.0 in Q1 2026, from $102.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $165.0 million in Q2 2023 to a low of $227000.0 in Q2 2024.
• A 5-year average of $43.7 million and a median of $411000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 99.86% — and 2025, when it surged 52738.33%.
• Tracing ENTA's Other Non-Current Liabilities over 5 years: stood at $414000.0 in 2022, then surged by 56.76% to $649000.0 in 2023, then sank by 63.79% to $235000.0 in 2024, then surged by 43654.04% to $102.8 million in 2025, then slumped by 99.73% to $278000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $278000.0 (Q1 2026), $102.8 million (Q4 2025), and $260000.0 (Q3 2025), per Business Quant data.